Healios KK (OTCMKTS:HLOSF – Get Rating) is one of 375 public companies in the ‘Biotechnology’ industry, but how does it compare to its peers? We will compare Healios KK to related companies based on strength of risk, valuation, earnings, profitability, dividends, institutional ownership and analysts’ rating.
Yield and Valuation
This table compares the Revenue, Earnings Per Share and Valuation for Healios KK and its competitors.
Gross Sales Net Income Price to Earnings Healios KK N/AN/A -32.57 Healios KK Competitors $160.93 million -$3.97 million 77.01
Healios KK’s competitors have higher sales but lower earnings than Healios KK. Healios KK is trading at a lower price-to-earnings ratio than its peers, suggesting that it is currently more affordable than other companies in its industry.
Insider and Institutional Property
20.3% of Healios KK shares are owned by institutional investors. In comparison, institutional investors own 27.3% of the shares of all “biotechnology” companies. Insiders own 24.3% of the shares of all “biotechnology” companies. Strong institutional ownership is an indication that hedge funds, large wealth managers, and endowments believe a company is poised for long-term growth. profitability
This table compares the net margins, return on equity and return on investments of Healios KK and its peers.
Net Margins Return on Equity Return on Investments Healios KK N/AN/AN/A Healios KK Competitor -994.13% -298.75% -21.34% Analyst Recommendations
This is a breakdown of the current valuations and price targets for Healios KK and its competitors, as reported by MarketBeat.
Selling Ratings Holding Ratings Buying Ratings Strong Buying Ratings Rating Score Healios KK 0 0 0 0 N/A Healios KK Competitors 573 1555 4279 40 2.59
As a group, “biotechnology” companies have a potential growth potential of 86.48%. Given the higher potential upside potential of Healios KK’s peers, analysts clearly believe that Healios KK presents less favorable growth prospects than its peers.
Summary
Healios KK’s rivals beat Healios KK in 5 of the 8 factors compared.
Healios KK company profile
(get rating)
Healios KK is engaged in the research and development, manufacture and sale of cell therapy and regenerative medicine products in Japan, Europe and the United States. The Company is also developing cellular and tissue-based products, including HLCR011 and HLCR012, which are iPSC regenerative drugs for the treatment of age-related macular degeneration. HLCL041, an iPSC regenerative drug to treat metabolic liver disease; and HLCM051, a regenerative drug for the treatment of ischemic stroke and acute respiratory distress syndrome, and HLCN061 for the treatment of solid tumors. Healios KK has a joint research agreement with Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, KK and changed its name to Healios KK in September 2013. Healios KK was founded in 2011 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Healios KK Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Healios KK and related companies with MarketBeat.com’s FREE daily email newsletter to obtain.
